Evidence map›Paper›PMID 38753221›Full record

ArticleInflammopharmacology2024

Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis.

Mengye Wu, Cuiping Li, Xue Zhou, Zhiyong Wu, Jianqi Feng, Xiaolu Guo, Rui Fang, Qinghai Lian, Ming Pan, Xiaorong Lai and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mengye Wu *The Biotherapy Center, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong, China.
Cuiping Li *The Biotherapy Center, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong, China.
Xue Zhou *Department of Ultrasonic Medicine, Guangzhou Women and Children's Medical Center, Guangzhou, 510623, Guangdong, China.
Zhiyong WuCollege of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Jianqi FengCenter for Stem Cells Translational Medicine, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, 518067, Guangdong, China.
Xiaolu GuoCenter for Stem Cells Translational Medicine, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, 518067, Guangdong, China.
Rui FangCenter for Stem Cells Translational Medicine, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, 518067, Guangdong, China.
Qinghai LianCell-Gene Therapy Translational Medicine Research Centre, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong, China.
Ming PanZhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.
Xiaorong LaiDepartment of Tumor Internal Medicine, Guangdong General Hospital Welfare Branch, Guangdong Academy of Medical Sciences, Guangzhou, 518067, Guangdong, China.
Yanwen PengThe Biotherapy Center, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, Guangdong, China. pengyw@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-3760-7397

Funding

Fundamental and Applied Basic Research of Guangzhou City-University (Institution) Projects 202201020461National Natural Science Foundation of China 82170216Sanming Project of Medicine in Shenzhen Nanshan SZSM202103012Science and Technology Program of Guangzhou 202102020738Science and Technology Program of Guangzhou 202102080468Shenzhen Nanshan District Science and Technology Program NS2022023
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBDs) are prevalent and debilitating diseases with limited clinical treatment strategies. Mesenchymal stem cell (MSCs) are pluripotent stem cells with self-renewal capability and multiple immunomodulatory effects, which make them a promising therapeutic approach for IBDs. Thus, optimization of MSCs regimes is crucial for their further clinical application. Wogonin, a flavonoid-like compound with extensive immunomodulatory and adjuvant effects, has been investigated as a potential pretreatment for MSCs in IBD treatment. In this study, we employed the DSS-induced acute colitis mouse model to compare the therapeutic effectiveness of MSCs in pretreated with or without wogonin and further explore the underlying mechanism. Compared to untreated MSCs, MSC

Indexed as

ColitisFlavanonesGlycolysisMesenchymal Stem CellsMice, Inbred C57BLAnimalsDextran SulfateDisease Models, AnimalMaleMesenchymal Stem Cell TransplantationMiceSignal TransductionDextran SulfateFlavanoneswogoninAKT signaling pathwayGlycolysisInflammatory bowel diseases (IBDs)Mesenchymal stem cells (MSCs)

Identifiers

PMID38753221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.